Correlation between the promoter basal core and precore mutations and HBsAg quantification in French blood donors infected with hepatitis B virus

Journal of Medical Virology

Volumn 87, Issue 3, 2015, Pages 529-535

  Pivert, A ^a   Servant Delmas, A ^b   Lunel Fabiani, F ^a   Le Guillou Guillemette, H ^a   Laperche, S ^b   Ducancelle, A ^a  

^a UNIVERSITÉ D'ANGERS   (France)

^b National Blood Transfusion Institute   (France)

Author keywords

Basal core promoter mutation; Blood donor; G1896A mutation; HBsAg titre; Hepatitis B

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; VIRUS DNA;

ADULT; AGE; ANTIBODY TITER; ARTICLE; BLOOD DONOR; CORRELATION ANALYSIS; DISEASE CARRIER; DRUG DEPENDENCE; FEMALE; GENE MUTATION; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS B VIRUS GENOTYPE A; HEPATITIS B VIRUS GENOTYPE B; HEPATITIS B VIRUS GENOTYPE C; HEPATITIS B VIRUS GENOTYPE D; HEPATITIS B VIRUS GENOTYPE F; HOSPITAL INFECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PROMOTER REGION; RISK FACTOR; SEX DIFFERENCE; SEXUAL TRANSMISSION; VERTICAL TRANSMISSION; VIRUS LOAD; VIRUS MUTANT; VIRUS MUTATION; ADOLESCENT; BLOOD; DNA SEQUENCE; FRANCE; GENETICS; ISOLATION AND PURIFICATION; MIDDLE AGED; POINT MUTATION; VIROLOGY; YOUNG ADULT;

HEPATITIS B VIRUS;

ADOLESCENT; ADULT; BLOOD DONORS; DNA, VIRAL; FEMALE; FRANCE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; MALE; MIDDLE AGED; POINT MUTATION; PROMOTER REGIONS, GENETIC; SEQUENCE ANALYSIS, DNA; VIRAL LOAD; YOUNG ADULT;

EID: 84921348780     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.24064     Document Type: Article

References (36)

1. Biswas A, Chandra PK, Datta S, Panigrahi R, Banerjee A, Chakrabarti S, Biswas K, Patra D, Bhattacharya P, Chakravarty R. 2008. Frequency and distribution of hepatitis B virus genotypes among eastern Indian voluntary blood donors: Association with precore and basal core promoter mutations. Hepatol Res 39:53-59.
2. Bruix J, Llovet JM. 2003. Hepatitis B virus and hepatocellular carcinoma. J Hepatol 39:S59-63.
3. Brunetto MR, Oliveri F, Colombatto P, Moriconi F, Ciccorossi P, Coco B, Romagnoli V, Cherubini B, Moscato G, Maina AM, Cavallone D, Bonino F. 2010. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology 139:483-490.
4. Candotti D, Opare-Sem O, Rezvan H, Sarkodie F, Allain JP. 2006. Molecular and serological characterization of hepatitis B virus in deferred Ghanaian blood donors with and without elevated alanine aminotransferase. J Viral Hepat 13:715-724.
5. Carman WF, Jacyna MR, Hadziyannis S, Karayiannis P, McGarvey MJ, Makris A, Thomas HC. 1989. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 2:588-591.
6. Chan HL, Wong VW, Wong GL, Tse CH, Chan H, YSung JJ. 2010. A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B. Hepatology 52:1232-1241.
7. Datta S, Biswas A, Chandra PK, Banerjee A, Panigrahi R, Mahapatra PK, Chakrabarti S, Panda CK, Chakravarty R. 2008. Molecular epidemiology and clinical significance of hepatitis B virus genotypes, core promoter and precore mutations in eastern India. Intervirology 51:275-284.
8. Davidson F, Lycett C, Sablon E, Petrik J, Dow BC. 2005. Hepatitis B virus genotypes and precore mutations in Scottish blood donors. Vox Sang 88:87-92.
9. Ducancelle A, Servant-Delmas A, Beuvelet T, Balan V, Pivert A, Maniez M, Laperche S, Lunel-Fabiani F. 2011. [Results of a novel real-time PCR, sequence analysis, Inno-LiPA line probe assays in the detection of hepatitis B virus G1896A precore mutation in French blood donors.]. Pathol Biol (Paris). 59:21-27.
10. EASL. 2012. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 57:167-185.
11. Friedt M, Gerner P, Lausch E, Trubel H, Zabel B, Wirth S. 1999. Mutations in the basic core promotor and the precore region of hepatitis B virus and their selection in children with fulminant and chronic hepatitis B. Hepatology 29:1252-1258.
12. Gandhe SS, Chadha MS, Walimbe AM, Arankalle VA. 2003. Hepatitis B virus: prevalence of precore/core promoter mutants in different clinical categories of Indian patients. J Viral Hepat 10:367-382.
13. Grandjacques C, Pradat P, Stuyver L, Chevallier M, Chevallier P, Pichoud C, Maisonnas M, Trepo C, Zoulim F. 2000. Rapid detection of genotypes and mutations in the pre-core promoter and the pre-core region of hepatitis B virus genome: Correlation with viral persistence and disease severity. J Hepatol 33:430-439.
14. Halfon P, Bourliere M, Pol S, Benhamou Y, Ouzan D, Rotily M, Khiri H, Renou C, Penaranda G, Saadoun D, Thibault V, Serpaggi J, Varastet M, Tainturier MH, Poynard T, Cacoub P. 2006. Multicentre study of hepatitis B virus genotypes in France: Correlation with liver fibrosis and hepatitis B e antigen status. J Viral Hepat 13:329-335.
15. Kao JH, Chen PJ, Lai MY, Chen DS. 2003. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology 124:327-334.
16. Kitab B, Essaid El, Feydi A, Afifi R, Trepo C, Benazzouz M, Essamri W, Zoulim F, Chemin I, Alj HS, Ezzikouri S, Benjelloun S. 2012. Variability in the precore and core promoter regions of HBV strains in Morocco: characterization and impact on liver disease progression. PLoS One 7:e42891(1-10). doi: 10.1371/journal.pone.0042891
17. Llovet JM, Burroughs A, Bruix J. 2003. Hepatocellular carcinoma. Lancet 362:1907-1917.
18. Lok AS, Akarca U, Greene S. 1994. Mutations in the pre-core region of hepatitis B virus serve to enhance the stability of the secondary structure of the pre-genome encapsidation signal. Proc Natl Acad Sci U S A 91:4077-4081.
19. Martinot-Peignoux M, Lapalus M, Asselah T, Marcellin P. 2013. The role of HBsAg quantification for monitoring natural history and treatment outcome. Liver Int 33:125-132.
20. McMahon BJ. 2014. Chronic hepatitis B virus infection. Med Clin North Am 98:39-54.
21. Moucari R, Mackiewicz V, Lada O, Ripault MP, Castelnau C, Martinot-Peignoux M, Dauvergne A, Asselah T, Boyer N, Bedossa P, Valla D, Vidaud M, Nicolas-Chanoine MH, Marcellin P. 2009a. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 49:1151-1157.
22. Moucari R, Martinot-Peignoux M, Mackiewicz V, Boyer N, Ripault MP, Castelnau C, Leclere L, Dauvergne A, Valla D, Vidaud M, Nicolas-Chanoine MH, Marcellin P. 2009b. Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-alpha2a. Antivir Ther 14:1183-1188.
23. Nguyen T, Thompson AJ, Bowden S, Croagh C, Bell S, Desmond PV, Levy M, Locarnini SA. 2010. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: A perspective on Asia. J Hepatol 52:508-513.
24. Okamoto H, Tsuda F, Akahane Y, Sugai Y, Yoshiba M, Moriyama K, Tanaka T, Miyakawa Y, Mayumi M. 1994. Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen. J Virol 68:8102-8110.
25. Papatheodoridis GV, Hadziyannis SJ. 2001. Diagnosis and management of pre-core mutant chronic hepatitis B. J Viral Hepat 8:311-321.
26. Pujol FH, Navas MC, Hainaut P, Chemin I. 2009. Worldwide genetic diversity of HBV genotypes and risk of hepatocellular carcinoma. Cancer Lett 286:80-88.
27. Servant-Delmas A, Mercier M, El Ghouzzi MH, Girault A, Bouchardeau F, Pillonel J, Laperche S. 2010. National survey of hepatitis B virus (HBV) polymorphism in asymptomatic HBV blood donors from 1999 to 2007 in France. Transfusion 50:2607-2618.
28. Tong S. 2005. Mechanism of HBV genome variability and replication of HBV mutants. J Clin Virol 34:S134-S138.
29. Truong BX, Seo Y, Yano Y, Ho PT, Phuong TM, Long DV, Son NT, Long NC, Kato H, Hayashi Y, Trach NK, Kasuga M. 2007. Genotype and variations in core promoter and pre-core regions are related to progression of disease in HBV-infected patients from Northern Vietnam. Int J Mol Med 19:293-299.
30. Tsai WL, Lo GH, Hsu PI, Lai KH, Lin CK, Chan HH, Chen WC, Cheng JS, Liu YC, Huang TS, Ger LP, Lin HH. 2008. Role of genotype and precore/basal core promoter mutations of hepatitis B virus in patients with chronic hepatitis B with acute exacerbation. Scand J Gastroenterol 43:196-201.
31. Utama A, Purwantomo S, Siburian MD, Dhenni R, Gani RA, Hasan I, Sanityoso A, Miskad UA, Akil F, Yusuf I, Achwan WA, Soemohardjo S, Lelosutan SA, Martamala R, Lukito B, Budihusodo U, Lesmana LA, Sulaiman A, Tai S. 2009. Hepatitis B virus subgenotypes and basal core promoter mutations in Indonesia. World J Gastroenterol 15:4028-4036.
32. Varghese V, Shahriar R, Rhee SY, Liu T, Simen BB, Egholm M, Hanczaruk B, Blake LA, Gharizadeh B, Babrzadeh F, Bachmann MH, Fessel WJ, Shafer RW. 2009. Minority variants associated with transmitted and acquired HIV-1 nonnucleoside reverse transcriptase inhibitor resistance: Implications for the use of second-generation nonnucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 52:309-315.
33. Vivekanandan P, Abraham P, Sridharan G, Chandy G, Shaji RV, Daniel D, Raghuraman S, Daniel HD, Subramaniam T. 2004. High frequency of the 1896 precore mutation in patients and blood donors with hepatitis B virus infection from the Indian subcontinent. Mol Diagn 8:51-56.
34. Vray M, Debonne JM, Sire JM, Tran N, Chevalier B, Plantier JC, Fall F, Vernet G, Simon FMbPS. 2006. Molecular epidemiology of hepatitis B virus in Dakar, J Med Virol 78:329-334.
35. Wang C, Mitsuya Y, Gharizadeh B, Ronaghi M, Shafer RW. 2007. Characterization of mutation spectra with ultra-deep pyrosequencing: Application to HIV-1 drug resistance. Genome Res 17:1195-1201.
36. Yang HI, Yeh SH, Chen PJ, Iloeje UH, Jen CL, Su J, Wang LY, Lu SN, You SL, Chen DS, Liaw YF, Chen CJ. 2008. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst 100:1134-1143.